Investor Presentation - First Six Months of 2021
22
Investor presentation First six months of 2021
Novo Nordisk®
Novo Nordisk's opportunity is in the large unmet needs across all
therapy areas in scope
DIABETES
~463 million
-6%
OBESITY
~650 million
-2%
HAEMOPHILIA
~0.5 million
-25%
People with
diabetes
People in good
control
People with People medically
obesity
treated
People with
haemophilia
People being
treated
OTHER SERIOUS
CHRONIC DISEASES
*
Gro
80% of diagnosed NASH
patients are obese
and 35% have T2DM
70% of diabetes
patients die from
atherosclerotic CVD
40% of patients
hospitalised for heart
failure are diabetic
~50% of the total CKD
population suffers from
diabetic nephropathy
NASH: Non-alcoholic steatohepatitis, T2DM: Type 2 diabetes mellitus, CVD: Cardiovascular disease, CKD: Chronic kidney disease. Note: All figures are global and good control defined as A1C that is less than 7%
Source: International Diabetes Federation; Diabetes Atlas 9th Edition 2019, IQVIA MIDAS 2017, World Federation of Haemophilia - Annual survey 2018; Abera SF et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015,
2017; Heart Disease and Stroke Statistics, American Heart Association, 2017; Williams CD et al. Prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilising ultrasound and liver biopsy, 2011;
Addressing the global burden of chronic kidney disease through clinical and translational research, 2014View entire presentation